In response to Dr. Ahdieh

Pain Practice

Volumn 8, Issue 4, 2008, Pages 330-

  Foster, Adriana ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HYDROCODONE; HYDROMORPHONE; OPIATE; OXYCODONE; OXYCODONE PLUS PARACETAMOL; OXYMORPHONE; PARACETAMOL;

DRUG CHOICE; DRUG CLEARANCE; DRUG METABOLISM; DRUG TREATMENT FAILURE; HUMAN; LETTER; OUTPATIENT CARE; PAIN;

EID: 48249100116     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2008.00218_2.x     Document Type: Letter

References (4)

1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004; 57: 287-297.
2. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, part II. Psychosomatics. 2003; 44: 515-520.
3. Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30: 1356-1358.
4. Chamberlin KW, Cottle M, Neville R, Tan J. Oral oxymorphone for pain management. Ann Pharmacother. 2007; 41: 1144-1152.